Long COVID Clinical Trial
Official title:
The Use of Incentive Spirometry (Triflow) in Patients With Long Covid
The aim of this clinical trial is to investigate the efficacy of Triflow in the rehabilitation of patients with long covid syndrome hospitalised in a rehabilitation center. Participants will be divided into 2 groups and follow their exercise regime until the day they are discharged from the rehabilitation center. The intervention group will participate in a rehabilitation program which includes upper and lower limbs exercises, cycle ergometer, walking and the use of triflow. The control group will participate in the same program but without the Triflow.
Status | Recruiting |
Enrollment | 70 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 23, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adults who were infected with COVID-19 in the last 6 months and were diagnosed with long-covid syndrome - Patients must be willing to give written consent for participation in the study - Negative rapid test for COVID-19 Exclusion Criteria: - History of diseases that do not allow exercise (e.g. unstable cardiac disease) - Age < 18 years of age - Significant cognitive and psychiatric impairments (inability to follow simple commands or give consent) - Lack of will to do the exercises or refuse to give consent |
Country | Name | City | State |
---|---|---|---|
Cyprus | Eden Resort Wellness Rehabilitation Center | Larnaca |
Lead Sponsor | Collaborator |
---|---|
European University Cyprus | Eden Resort Wellness Rehabilitation Center |
Cyprus,
Basoglu OK, Atasever A, Bacakoglu F. The efficacy of incentive spirometry in patients with COPD. Respirology. 2005 Jun;10(3):349-53. doi: 10.1111/j.1440-1843.2005.00716.x. — View Citation
Eltorai AEM, Szabo AL, Antoci V Jr, Ventetuolo CE, Elias JA, Daniels AH, Hess DR. Clinical Effectiveness of Incentive Spirometry for the Prevention of Postoperative Pulmonary Complications. Respir Care. 2018 Mar;63(3):347-352. doi: 10.4187/respcare.05679. Epub 2017 Dec 26. — View Citation
Franklin E, Anjum F. Incentive Spirometer and Inspiratory Muscle Training. 2023 Apr 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK572114/ — View Citation
Imamura M, Mirisola AR, Ribeiro FQ, De Pretto LR, Alfieri FM, Delgado VR, Battistella LR. Rehabilitation of patients after COVID-19 recovery: An experience at the Physical and Rehabilitation Medicine Institute and Lucy Montoro Rehabilitation Institute. Clinics (Sao Paulo). 2021 Jun 14;76:e2804. doi: 10.6061/clinics/2021/e2804. eCollection 2021. — View Citation
Mohamed AA, Alawna M. Role of increasing the aerobic capacity on improving the function of immune and respiratory systems in patients with coronavirus (COVID-19): A review. Diabetes Metab Syndr. 2020 Jul-Aug;14(4):489-496. doi: 10.1016/j.dsx.2020.04.038. Epub 2020 Apr 28. — View Citation
Restrepo RD, Wettstein R, Wittnebel L, Tracy M. Incentive spirometry: 2011. Respir Care. 2011 Oct;56(10):1600-4. doi: 10.4187/respcare.01471. — View Citation
Seyller H, Gottlieb M, Colla J. A breath of fresh air: The role of incentive spirometry in the treatment of COVID-19. Am J Emerg Med. 2021 Oct;48:369. doi: 10.1016/j.ajem.2021.01.084. Epub 2021 Feb 1. No abstract available. — View Citation
Siddiq MAB, Rathore FA, Clegg D, Rasker JJ. Pulmonary Rehabilitation in COVID-19 patients: A scoping review of current practice and its application during the pandemic. Turk J Phys Med Rehabil. 2020 Nov 9;66(4):480-494. doi: 10.5606/tftrd.2020.6889. eCollection 2020 Dec. — View Citation
Spielmanns M, Pekacka-Egli AM, Schoendorf S, Windisch W, Hermann M. Effects of a Comprehensive Pulmonary Rehabilitation in Severe Post-COVID-19 Patients. Int J Environ Res Public Health. 2021 Mar 7;18(5):2695. doi: 10.3390/ijerph18052695. — View Citation
Toor H, Kashyap S, Yau A, Simoni M, Farr S, Savla P, Kounang R, Miulli DE. Efficacy of Incentive Spirometer in Increasing Maximum Inspiratory Volume in an Out-Patient Setting. Cureus. 2021 Oct 4;13(10):e18483. doi: 10.7759/cureus.18483. eCollection 2021 Oct. — View Citation
Zampogna E, Paneroni M, Belli S, Aliani M, Gandolfo A, Visca D, Bellanti MT, Ambrosino N, Vitacca M. Pulmonary Rehabilitation in Patients Recovering from COVID-19. Respiration. 2021;100(5):416-422. doi: 10.1159/000514387. Epub 2021 Mar 30. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Barthel Index | Measures performance in activities of daily living (eg.stairs, dressing/undressing, washing,eating). Score from 0 to 100, where 0 indicates total dependence and 100 total independence with activities of daily living. | on admission day | |
Primary | Barthel Index | Measures performance in activities of daily living (eg.stairs, dressing/undressing, washing,eating). Score from 0 to 100, where 0 indicates total dependence and 100 total independence with activities of daily living. | on discharge day | |
Primary | Dyspnoea (Medical Research Council Dyspnoea Scale) | Assess dyspnoea via MRC dyspnoea scale. The participants grade their dyspnoea on a scale of 1 to 5. The bigger the number, the worse their dyspnoea is | on admission day | |
Primary | Dyspnoea (Medical Research Council Dyspnoea Scale) | Assess dyspnoea via MRC dyspnoea scale. The participants grade their dyspnoea on a scale of 1 to 5. The bigger the number, the worse their dyspnoea is | on discharge day | |
Primary | Peak Flow Meter | Assess the respiratory function via peak flow meter. The participants will take a deep breath and blow the air out into the peak flow meter. The higher the score the better their respiratory function is | on admission day | |
Primary | Peak Flow Meter | Assess the respiratory function via peak flow meter. The participants will take a deep breath and blow the air out into the peak flow meter. The higher the score the better their respiratory function is | on discharge day | |
Secondary | Number of hospitalisation days | Number of days participants stay in the rehabilitation center | on discharge day | |
Secondary | Muscle strength (Hand Grip) | Assess muscle strength for the upper extremities via hand-held dynamometer | on admission day | |
Secondary | Muscle strength (Hand Grip) | Assess muscle strength for the upper extremities via hand-held dynamometer | on discharge day | |
Secondary | Muscle strength and endurance (30 seconds Sit to stand) | Assess muscle strength for the lower extremities and endurance via 30 seconds sit to stand. The participants will have to stand up from a chair without using their arms as many times as they can in 30 seconds. The more times the better their muscle strength and endurance | on admission day | |
Secondary | Muscle strength and endurance (30 seconds Sit to stand) | Assess muscle strength for the lower extremities and endurance via 30 seconds sit to stand. The participants will have to stand up from a chair without using their arms as many times as they can in 30 seconds. The more times the better their muscle strength and endurance | on discharge day | |
Secondary | Balance (Berg Balance) | Assess via Berg Balance Questionnaire, a total of 14 items that asess balance. from 0 to 56, the higher the score the better balance a person has and has a smaller risk for falls. | on admission day | |
Secondary | Balance (Berg Balance) | Assess via Berg Balance Questionnaire, a total of 14 items that asess balance. from 0 to 56, the higher the score the better balance a person has and has a smaller risk for falls. | on discharge day | |
Secondary | Cardiorespiratory fitness (Six minutes walking test) | Assess the cardiorespiratory fitness via 6 minutes walking test. The participants have to walk for 6 mins independently and the distance they cover is measured. The bigger the distance the better cardiorespiratory fitness. | on admission day | |
Secondary | Cardiorespiratory fitness (Six minutes walking test) | Assess the cardiorespiratory fitness via 6 minutes walking test. The participants have to walk for 6 mins independently and the distance they cover is measured. The bigger the distance the better cardiorespiratory fitness. | on discharge day | |
Secondary | Quality of life (EQ-5D-5L) | Assess via EQ-5D-5L questionnaire, it has 6 components (movement,self-care, everyday activities, pain/discomfort, stress/depression, and a scale from 0 to 100 for participants to score how they perceive their health on the day( 0 indicates worst heath and 100 best health) | on admission day | |
Secondary | Quality of life (EQ-5D-5L) | Assess via EQ-5D-5L questionnaire, it has 6 components (movement,self-care, everyday activities, pain/discomfort, stress/depression, and a scale from 0 to 100 for participants to score how they perceive their health on the day( 0 indicates worst heath and 100 best health) | on discharge day | |
Secondary | Fatigue (Multidimensional fatigue inventory) | Assess the feeling of fatigue via Multidimensional fatigue inventory. it has 20 questions with a scale from 1(yes that is true) to 5 (no that is not true) | on admission day | |
Secondary | Fatigue (Multidimensional fatigue inventory) | Assess the feeling of fatigue via Multidimensional fatigue inventory. it has 20 questions with a scale from 1(yes that is true) to 5 (no that is not true) | on discharge day | |
Secondary | Timed up and Go | Assesses mobility and fall risk. Participants have to walk 3m, the shorter the time the better their mobility | on admission day | |
Secondary | Timed up and Go | Assesses mobility and fall risk. Participants have to walk 3m, the shorter the time the better their mobility | on discharge day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05926505 -
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Completed |
NCT05552612 -
Health-related Quality of Life and Long COVID
|
||
Completed |
NCT05531019 -
COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A
|
N/A | |
Not yet recruiting |
NCT04949386 -
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
|
Phase 2 | |
Recruiting |
NCT06118112 -
Living With Long COVID: LONGCOVID-EXPERIENCE
|
||
Completed |
NCT05185674 -
Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
|
||
Active, not recruiting |
NCT05965752 -
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
|
N/A | |
Active, not recruiting |
NCT05965739 -
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
|
N/A | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Recruiting |
NCT05606211 -
Pain in Long COVID-19: The Role of Sleep
|
||
Active, not recruiting |
NCT05713266 -
Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
|
||
Completed |
NCT05679505 -
Vagus Nerve Stimulation for Post-COVID Syndrome
|
N/A | |
Completed |
NCT05601180 -
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
|
N/A | |
Not yet recruiting |
NCT06045338 -
Mind Body Intervention for Long COVID
|
N/A | |
Recruiting |
NCT06091358 -
Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.
|
N/A | |
Recruiting |
NCT05566392 -
Longterm Influence of Pediatric Long COVID Syndrome
|
||
Recruiting |
NCT05855369 -
Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss
|
Phase 2/Phase 3 | |
Recruiting |
NCT05572346 -
Digital App for Telerehabilitation in Respiratory Diseases
|
||
Recruiting |
NCT06316843 -
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
|
Phase 2 |